For release at 6:30 a.m.
Robert F. Doman, President & CEO — 978.909.2216
Richard Christopher, VP Finance & CFO — 978.909.2211
Chad Rubin, Investor Relations Contact, The Trout Group LLC — 646.378.2947
DUSA Pharmaceuticals Reports
Second Quarter 2010 Corporate Highlights and Financial Results
Domestic Kerastick ® revenues up 35% year over year;
Company generates Q2 profits
Conference call will be held today, August 3 rd , at 8:30am EDT
WILMINGTON, Mass. — August 3, 2010 — DUSA Pharmaceuticals, Inc. ® (NASDAQ GM: DUSA), a
dermatology company that is developing and marketing Levulan ® Photodynamic Therapy (PDT) and other
products focused on patients with common skin conditions, reported today its corporate highlights and financial
results for the second quarter ended June 30, 2010.
Financial highlights for the second quarter and first half of the year include:
Domestic Kerastick ® revenues totaled $7.6 million for the second quarter of 2010, representing a
$1.9 million or 35% improvement as compared to the second quarter of 2009. First half 2010 domestic
Kerastick ® revenues totaled $15.1 million, representing a $3.8 million or 34% improvement year-over-
Kerastick ® gross margins for the second quarter of 2010 reached a record high of 88%.
The Company generated net income on both a GAAP and non-GAAP basis during the second quarter of
o GAAP net income for the second quarter of 2010 was $0.2 million, representing a $1.0 million
o Non-GAAP net income for the second quarter of 2010 was $0.6 million, also representing a
$1.0 million improvement year-over-year.
The Company experienced significant bottom line improvement on both a GAAP and non-GAAP basis
for the first half of the year.
o GAAP net loss for the first half of 2010 was $0.2 million, representing a $2.2 million improvement
o Non-GAAP net income for the first half of 2010 was